NCT00560794 Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) Status COMPLETED Phase PHASE2
NCT00557193 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE3
NCT00552825 Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children Status COMPLETED Phase N/A
NCT00549848 Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE3
NCT00539695 Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD Status COMPLETED Phase PHASE2
NCT00529360 Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL Status COMPLETED Phase PHASE1/PHASE2
NCT00526409 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE4
NCT00526305 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Status COMPLETED Phase PHASE4
NCT00522990 Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Status TERMINATED Phase PHASE1/PHASE2
NCT00514722 Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies Status TERMINATED Phase NA
NCT00513318 Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies Status TERMINATED Phase N/A
NCT00513175 Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia Status COMPLETED Phase N/A
NCT00494897 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE4
NCT00466895 Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. Status COMPLETED Phase PHASE1
NCT00460694 Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies Status COMPLETED Phase PHASE1/PHASE2
NCT00440726 Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) Status COMPLETED Phase PHASE1/PHASE2